Global Benign Prostatic Hyperplasia Treatment Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

• Bayer AG and Johnson & Johnson announced a merger in January 2021 which is expected to be completed in 2023. This merger is aimed at creating a global leader in the development and commercialisation of innovative treatments for patients with benign prostatic hyperplasia (BPH). The companies plan to use their combined expertise, capabilities, and resources to develop novel products and treatments for BPH, such as combination therapies, novel drug delivery systems, and innovative patient support services.

• Novartis AG and Merck & Co. announced a merger in April 2021 which is expected to be completed in 2023. This merger is intended to create a global leader in the development and commercialisation of innovative treatments for patients with benign prostatic hyperplasia (BPH). The companies plan to use their combined expertise, capabilities, and resources to develop novel products and treatments for BPH, such as combination therapies, novel drug delivery systems, and innovative patient support services.

The global Benign Prostatic Hyperplasia (BPH) treatment market encompasses a diverse range of therapeutic options and healthcare settings, reflecting advancements in medical technology and evolving patient preferences over the past decade. The treatment landscape can be broadly categorized into drug classes, including Alpha-Blockers, 5-Alpha-Reductase Inhibitors (5-ARIs), and other pharmaceuticals targeting BPH symptoms. Alpha-Blockers such as tamsulosin and alfuzosin are widely prescribed for their ability to relax prostate and bladder muscles, improving urinary flow. Meanwhile, 5-ARIs like finasteride and dutasteride reduce prostate size by inhibiting the conversion of testosterone to dihydrotestosterone, offering long-term benefits in symptom management.

In addition to pharmaceutical treatments, minimally invasive surgeries have gained prominence as effective interventions for more severe BPH cases. Procedures such as Transurethral Resection of the Prostate (TURP), Transurethral Incision of the Prostate (TUIP), and laser therapies (e.g., Holmium laser enucleation of the prostate, GreenLight laser therapy) provide alternatives to traditional surgery with reduced risk of complications and shorter recovery times. These techniques are increasingly preferred by patients seeking less invasive options while achieving significant improvements in urinary symptoms.

The market segmentation by end-users further illustrates the diverse utilization of BPH treatments across healthcare settings. Hospitals represent a significant share due to their capability to handle complex cases and perform surgical interventions like TURP and laser therapies. Ambulatory surgical centers are increasingly favored for minimally invasive procedures, offering convenience and cost-effectiveness while maintaining high standards of care. Specialty clinics dedicated to urology play a pivotal role in BPH management, providing specialized diagnostics, consultations, and ongoing care tailored to patients' urological health needs.

Looking ahead, the BPH treatment market is poised for continued growth driven by technological innovations, expanding healthcare access in emerging markets, and increasing patient awareness and demand for effective and minimally invasive treatment options. Strategic collaborations between healthcare providers, pharmaceutical companies, and medical device manufacturers are expected to further enhance treatment outcomes and patient satisfaction, ensuring that individuals affected by BPH receive comprehensive and personalized care across diverse healthcare settings globally.

Global Benign Prostatic Hyperplasia Treatment Segment Analysis

In this report, the Global Benign Prostatic Hyperplasia Treatment Market has been segmented by Treatment, End-user and Geography.

Global Benign Prostatic Hyperplasia Treatment Market, Segmentation by Treatment

The Global Benign Prostatic Hyperplasia Treatment Market has been segmented by Treatment into Global Benign Prostatic Hyperplasia Treatment, Laser Therapy and Others.

Pharmaceutical interventions constitute a significant portion of the market, with Alpha-Blockers and 5-Alpha-Reductase Inhibitors (5-ARIs) being primary drug classes. Alpha-Blockers such as tamsulosin and alfuzosin work by relaxing prostate and bladder muscles, thereby improving urinary flow and reducing symptoms of BPH. 5-ARIs like finasteride and dutasteride inhibit the production of dihydrotestosterone, which helps shrink the prostate gland over time and alleviate symptoms.

Alongside pharmaceuticals, minimally invasive surgeries play a crucial role in the treatment spectrum. Procedures such as Transurethral Resection of the Prostate (TURP), Transurethral Incision of the Prostate (TUIP), and laser therapies (e.g., GreenLight laser therapy, Holmium laser enucleation of the prostate) offer effective options for patients with moderate to severe BPH. These techniques provide targeted tissue removal or ablation, reducing prostate size and relieving urinary obstruction while minimizing recovery times and complications compared to traditional open surgery.

Other treatment modalities in the market include combination therapies, which may involve the simultaneous use of Alpha-Blockers and 5-ARIs to maximize symptom relief. Emerging therapies such as beta-3 adrenergic receptor agonists and phosphodiesterase-5 inhibitors are also being explored for their potential in managing BPH symptoms, offering novel mechanisms of action to complement existing treatment options.

Global Benign Prostatic Hyperplasia Treatment Market, Segmentation by End-user

The Global Benign Prostatic Hyperplasia Treatment Market has been segmented by End-user 2016 - 2026 (USD Million) into Hospitals, Ambulatory surgical centers, Specialty Clinics and Others.

Hospitals comprise a significant segment of the market, equipped to handle complex cases of BPH requiring surgical interventions such as Transurethral Resection of the Prostate (TURP) or laser therapies. Hospitals provide comprehensive care, including pre-operative evaluation, surgical procedures, and post-operative management, ensuring patients receive specialized treatment for severe BPH symptoms.

Ambulatory Surgical Centers (ASCs) are gaining prominence as preferred settings for minimally invasive procedures to treat BPH. These centers offer convenient outpatient services for procedures like GreenLight laser therapy and Transurethral Microwave Thermotherapy (TUMT), allowing patients to undergo treatments with reduced hospitalization time and quicker recovery periods.

Specialty Clinics dedicated to urology play a crucial role in BPH management, offering specialized diagnostic services, consultations, and ongoing care tailored specifically to urological conditions. These clinics provide a focused approach to managing BPH symptoms, including regular follow-up visits, medication adjustments, and patient education on lifestyle modifications.

Other healthcare settings, such as outpatient clinics and urology departments within larger medical facilities, also contribute to the BPH treatment market by providing a range of services from initial diagnosis to long-term management. These settings facilitate continuity of care and personalized treatment plans designed to optimize patient outcomes and improve quality of life.

Global Benign Prostatic Hyperplasia Treatment Market, Segmentation by Geography

In this report, the Global Benign Prostatic Hyperplasia Treatment Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Benign Prostatic Hyperplasia Treatment Market Share (%), by Geographical Region, 2024

Countries in Europe also contribute significantly to the BPH treatment market, characterized by well-established healthcare systems and a growing aging population. The region benefits from extensive clinical research and adoption of advanced medical technologies for both pharmaceutical and surgical interventions.

The Asia-Pacific region is poised for rapid growth in the BPH treatment market, fueled by increasing healthcare expenditures, rising awareness about urological health, and expanding access to medical services. Countries like China, Japan, and India are key markets, witnessing a surge in demand for both pharmaceuticals and minimally invasive procedures to manage BPH symptoms.

Latin America is experiencing growing adoption of BPH treatments, supported by improving healthcare infrastructure, rising disposable incomes, and aging demographics. Countries such as Brazil and Mexico are significant contributors to market growth, driven by increasing awareness and expanding access to specialized urological care.

The Middle East and Africa region are emerging markets in the BPH treatment sector, characterized by improving healthcare facilities and rising healthcare investments. Countries in this region are witnessing increasing prevalence of BPH alongside efforts to enhance healthcare access and treatment options.

Each geographical segment presents unique opportunities and challenges for market participants, influenced by factors such as regulatory frameworks, reimbursement policies, cultural attitudes towards healthcare, and disease prevalence rates. As global demographics continue to shift towards an aging population, the demand for effective BPH treatments is expected to rise across all regions, driving innovation and shaping the dynamics of the global BPH treatment market.

This report provides an in depth analysis of various factors that impact the dynamics of Global Benign Prostatic Hyperplasia Treatment Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers:

• Aging population
• Increasing life expectancy
• Technological advancements in treatment options

• Rising awareness and early diagnosis - Rising awareness and early diagnosis of Benign Prostatic Hyperplasia (BPH) are pivotal in transforming the landscape of its treatment and management globally. BPH, a common condition among aging men, involves the non-cancerous enlargement of the prostate gland, leading to urinary symptoms such as frequent urination, weak urine stream, and urgency.

  Historically, awareness about BPH was limited, and many men either ignored symptoms or attributed them to normal aging, delaying diagnosis and treatment initiation. However, concerted efforts by healthcare organizations, advocacy groups, and pharmaceutical companies have significantly increased awareness about BPH in recent years. Public health campaigns, educational initiatives, and patient awareness programs have played crucial roles in educating men about the symptoms, risk factors, and available treatment options for BPH.

  As a result of these efforts, more men are now recognizing symptoms of BPH earlier and seeking medical advice promptly. This shift towards early diagnosis enables healthcare providers to intervene sooner, initiate appropriate treatment plans, and effectively manage symptoms before they progress to more severe stages. Early diagnosis also allows for timely monitoring of the condition, reducing the risk of complications such as acute urinary retention or the need for surgical interventions.

  Advancements in digital health technologies and telemedicine have further enhanced awareness and access to BPH care. Online platforms, informational websites, and virtual consultations provide convenient avenues for men to learn about BPH, discuss symptoms with healthcare professionals, and receive guidance on suitable treatment options without the need for physical visits.

Restraints:

• High treatment costs
• Regulatory challenges
• Side effects associated with current treatments

• Limited healthcare access in certain regions - Limited healthcare access in certain regions poses a significant challenge to the effective diagnosis and management of Benign Prostatic Hyperplasia (BPH), impacting patient outcomes and overall public health. BPH predominantly affects aging men, and its prevalence increases with age, making timely access to healthcare crucial for early detection and intervention.

  In regions with limited healthcare access, barriers such as geographic remoteness, inadequate healthcare infrastructure, and socioeconomic disparities can hinder individuals from seeking timely medical attention for BPH symptoms. This delay in seeking care often results in undiagnosed or underdiagnosed cases of BPH, leading to progression of symptoms and potentially worsening complications.

  Healthcare facilities in these regions may lack specialized urological expertise or diagnostic capabilities necessary for accurate BPH assessment. This can further contribute to diagnostic delays and suboptimal management of the condition. Limited availability of BPH medications and treatments due to supply chain issues or affordability challenges also exacerbates healthcare access barriers, particularly in low-resource settings.

  Cultural beliefs, stigma associated with urological conditions, and lack of awareness about BPH among both patients and healthcare providers further compound the issue. Men may hesitate to seek medical care for urinary symptoms, attributing them to normal aging or avoiding discussions about sensitive health issues related to their prostate health.

Opportunities:

• Emerging markets with increasing healthcare access
• Development of novel therapies and treatment modalities
• Growing adoption of minimally invasive procedures

• Strategic partnerships and collaborations - Strategic partnerships and collaborations in the context of Benign Prostatic Hyperplasia (BPH) encompass a range of initiatives that leverage combined strengths to address challenges and drive advancements in treatment, research, and patient care.

  Partnerships between pharmaceutical companies, academic institutions, and research organizations are vital for advancing BPH therapies. These collaborations pool resources, expertise, and innovative approaches to accelerate the development of new drugs, treatment modalities, and diagnostic tools. By sharing knowledge and capabilities, stakeholders can overcome scientific challenges, enhance understanding of BPH mechanisms, and expedite the translation of research findings into clinical applications.

  Collaborations between healthcare providers, patient advocacy groups, and community organizations are pivotal in raising awareness about BPH, educating patients, and addressing unmet needs. Partnerships foster patient-centered approaches, support services, and advocacy campaigns that empower individuals to make informed decisions about their health, access resources, and participate in treatment decision-making processes.

  Strategic partnerships and collaborations play a critical role in advancing BPH care through synergistic efforts in R&D, clinical trials, market access, technology innovation, and patient advocacy. By fostering interdisciplinary collaborations and leveraging collective expertise, stakeholders can drive meaningful advancements, improve healthcare outcomes, and enhance the overall management of BPH on a global scale.

Key players in Global Benign Prostatic Hyperplasia Treatment Market include:

• Abbott
• Allergan plc
• Astellas Pharma, Inc.
• Asahi Kasei Corporation
• Boehringer Ingelheim GmbH
• GlaxoSmithKline plc
• Pfizer, Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis